Not logged in Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active ulcerative colitis: results from the two Phase 3 placebo-controlled ABTECT induction trials Atreya, R.; Sands, B. E.; Rubin, D. T.; Dubinsky, M. C.; Armuzzi, A.; Treton, X.; Cataldi, F.; Jacobstein, D.; Rabbat, C.; Shan, K.; Hlavaty, T.; Witek, R.; Dulai, P.; Danese, S. Share Save
Pooled analysis of efficacy and safety of once-daily oral obefazimod in North American patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials Sands, B. E.; Dubinsky, M. C.; Cataldi, F.; Jacobstein, D.; Rabbat, C.; Shan, K.; Panaccione, R.; Ritter, T. E.; Siddiqui, J.; Duvall, G. A.; Dulai, P. Share Save
Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 phase 3 trials Heeren, S.; Dulai, P.; Neneman, B.; Bunganic, B.; Pumprla, J.; Cataldi, F.; Jacobstein, D.; Rabbat, C.; Shan, K.; Peyrin-Biroulet, L. Share Save
Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials Siegmund, B.; Atreya, R.; Cataldi, F.; Jacobstein, D.; Santo, J.; Rabbat, C.; Shan, K.; Miheller, P.; Gilletta De Saint Joseph, C.; Wojnarska, B. G.; Verstockt, B.; Magro, F.; Dulai, P. Share Save
Unsupervised Machine Learning to Identify Distinct Response Patterns to Guselkumab in Participants With Crohn's Disease: Post Hoc Analysis of the Pooled GRAVITI and GALAXI 2/3 Studies Dulai, Parambir S.; D'haens, Geert; Reinisch, Walter; Hart, Ailsa; Rani, Sudheer; Olurinde, Mobolaji; Van Rampelbergh, Rian; Gao, Long-Long; Yang, Zijiang; Hoops, Timothy; Valiathan, Chandni; Schreiber, Stefan Share Save
Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2) Sands, Bruce E.; Danese, Silvio; Peyrin-Biroulet, Laurent; Dubinsky, Marla; Hisamatsu, Tadakazu; Tilg, Herbert; Atreya, Raja; Armuzzi, Alessandro; Treton, Xavier; Baert, Filip; Seidler, Ursula; Cataldi, Fabio; Jacobstein, Doug; Rabbat, Christopher J.; Shan, Kejia; Duvall, George Aaron; Siegmund, Britta; Dulai, Parambir S.; Rubin, David; Vermeire, Severine Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Baseline Characteristics Associated With Probability of Remission and Greater Absolute Benefit of Treatment With Afimkibart (RO7790121/RG6631) Allegretti, Jessica R.; Peyrin-Biroulet, Laurent; Danese, Silvio; Dulai, Parambir S.; Banerjee, Anindita; Chandra, Deepa E.; Peeva, Elena; Neelakantan, Srividya; Vincent, Michael S.; Hung, Kenneth; Ursos, Lyann; Schiffman, Courtney; Bojic, Daniela; Lasch, Karen; Sands, Bruce E. Share Save
Evaluation of the Relationship Between Endoscopic Disease Severity and Treatment Choice for Patients With Ulcerative Colitis Using a Real-World Data Set Linked to Endoscopic Videos Evaluated With Computer Vision Dulai, Parambir S.; Arai, Ronen; Baxi, Shrujal; Thomason, Darren; Wang, Yeli; McCue, Maggie; Blair, Chris; Young, Lisa; Gower, Megan; Vajnik, Vijay Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}